

# Antonio Lupo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2399170/publications.pdf>

Version: 2024-02-01

30  
papers

1,170  
citations

567281

15  
h-index

477307

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

3472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Small Creatinine Shift Predicts Contrast-Induced Acute Kidney Injury and Persistent Renal Damage after Percutaneous Coronary Procedures. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 305-311.	0.8	7
2	Interleukin-27 is a potential marker for the onset of post-transplant malignancies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 157-166.	0.7	9
3	mTOR Inhibition Role in Cellular Mechanisms. <i>Transplantation</i> , 2018, 102, S3-S16.	1.0	26
4	Assessment of physical performance and body composition in male renal transplant patients. <i>Journal of Nephrology</i> , 2018, 31, 613-620.	2.0	5
5	A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?. <i>Journal of Nephrology</i> , 2018, 31, 297-306.	2.0	8
6	SP783IMPACT OF THE MAINTENANCE IMMUNOSUPPRESSIVE THERAPY ON THE FECAL MICROBIOME OF RENAL TRANSPLANT RECIPIENTS: COMPARISON BETWEEN AN EVEROLIMUS- VERSUS A STANDARD TACROLIMUS-BASED REGIMEN. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i607-i607.	0.7	0
7	In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1250.	4.1	8
8	New non-renal congenital disorders associated with medullary sponge kidney (MSK) support the pathogenic role of GDNF and point to the diagnosis of MSK in recurrent stone formers. <i>Urolithiasis</i> , 2017, 45, 359-362.	2.0	10
9	Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease. <i>BioMed Research International</i> , 2016, 2016, 1-16.	1.9	13
10	Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. <i>Journal of Nephrology</i> , 2016, 29, 881-891.	2.0	23
11	Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. <i>Diabetes</i> , 2016, 65, 803-817.	0.6	131
12	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. <i>Nature Communications</i> , 2016, 7, 10023.	12.8	412
13	Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro. <i>BMC Gastroenterology</i> , 2015, 15, 118.	2.0	15
14	A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation. <i>Journal of Pathology</i> , 2015, 237, 72-84.	4.5	40
15	The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bone-vessel liaison. <i>Journal of Nephrology</i> , 2015, 28, 549-555.	2.0	35
16	Mitochondria: a new therapeutic target in chronic kidney disease. <i>Nutrition and Metabolism</i> , 2015, 12, 49.	3.0	96
17	Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in "Omics" Medicine. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4281-4305.	4.1	23
18	Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells. <i>Journal of Nephrology</i> , 2015, 28, 431-440.	2.0	12

#	ARTICLE	IF	CITATIONS
19	NLRP3 Inflammasome Activation in Dialyzed Chronic Kidney Disease Patients. PLoS ONE, 2015, 10, e0122272.	2.5	70
20	Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects. Toxins, 2014, 6, 869-891.	3.4	36
21	Dialysis-related transcriptomic profiling: The pivotal role of heparanase. Experimental Biology and Medicine, 2014, 239, 52-64.	2.4	12
22	Single-side renal sympathetic denervation to treat malignant refractory hypertension in a solitary kidney patient. Journal of Nephrology, 2014, 27, 713-716.	2.0	3
23	mTOR inhibitors and renal allograft: Yin and Yang. Journal of Nephrology, 2014, 27, 495-506.	2.0	23
24	A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients. BMC Medical Genomics, 2013, 6, 17.	1.5	32
25	Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. Journal of Translational Medicine, 2013, 11, 292.	4.4	24
26	Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors. Clinical and Developmental Immunology, 2013, 2013, 1-13.	3.3	65
27	Influence of haemodialysis on the NT-proBNP plasma concentration. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1414-5.	2.3	3
28	The fate of glyoxal and methylglyoxal in peritoneal dialysis. Journal of Mass Spectrometry, 2006, 41, 405-408.	1.6	5
29	Red blood cells and platelet membrane fatty acids in non-dialyzed and dialyzed uremies. Clinica Chimica Acta, 1992, 211, 155-166.	1.1	21
30	Nephrotic Syndrome During 2-Mercapto-Propionyl-Glycine (Thiola) Therapy. Nephron, 1981, 28, 96-99.	1.8	3